Regulatory Press Releases
2025
Revenue amounted to 138.8 MSEK (127.9), an increase of 8.5 percent, of which a negative organic growth of 1.9 percent. The quarter was negatively impacted by the phase-out of non-strategic products in surgical instruments that began in early 2025 and a negative currency effect. Adjusted for these two factors, underlying organic growth would have amounted to 7.3 percent. “We had a continued strong...
2025-10-15 08:00
Stille AB announces new Executive Management and group structure
Stille AB (publ) announces new Executive Management team, with the appointment of Niklas Tyrén as Group CFO and Martin Richardson as Group COO. Stille AB today announces a new Executive Management and group structure to support the company’s continued international growth. The new organization strengthens group capabilities in Finance, Operations and QA/RA. We are announcing the appointment...
2025-09-18 16:00
Johan Lundholm to leave his Position as “Business Unit Manager – Surgical Tables” of Stille
Stille AB (publ) informs that Johan Lundholm has decided to leave his position as Business Unit Manager for Surgical Tables of Stille to pursue a new opportunity outside the company. "I would like to thank Johan for his contributions over the past four years and wish him all the best in his future endeavors. He has played an important role in driving the commercial development of the surgical...
2025-08-01 14:00
Stille completes the acquisition of Surgical Holdings
Stille AB (publ) (“Stille”) today confirms that the previously announced acquisition of Surgical Holdings Ltd (“Surgical Holdings”) has been completed. All closing conditions have been satisfied, and the shares have now been transferred to Stille. As previously communicated, the total consideration of c. GBP 7.7 million (corresponding to c. SEK 99.4 million) on a cash and debt-free...
2025-07-17 08:00
Stille AB: Interim Report Q2 2025
Stille AB (publ) today presents the report for the second quarter 2025. Revenue amounted to 124.7 MSEK (142.6). Order intake remained strong but was impacted by continued supply-chain constraints, the phase-out of non-strategic products, and currency headwinds. “Order intake remained strong and largely in line with our growth targets, providing a solid foundation for recovery,” says Ulrik...